Xalkori (Crizotinib) Patent Expiration, LOE Window & CMS Spending

Xalkori (Crizotinib) by Pfizer: FDA Orange Book core substance LOE 2029-11-06, 0 AB generics, $71.4M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN202570 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2029-11-06
Last Listed Patent or Exclusivity Date2029-11-06
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$71.4M
2024 Medicare Part D Spend$58.9M
2024 Medicaid Spend$12.5M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 21.2% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.